avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)
Phase 3Completed 0 watching 0 views this weekπ Rising
77
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Thrombocytopenia Associated With Liver Disease
Conditions
Thrombocytopenia Associated With Liver Disease
Trial Timeline
Nov 1, 2013 β Feb 21, 2017
NCT ID
NCT01976104About avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count) is a phase 3 stage product being developed by Eisai for Thrombocytopenia Associated With Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01976104. Target conditions include Thrombocytopenia Associated With Liver Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01972529 | Phase 3 | Completed |
| NCT01976104 | Phase 3 | Completed |
Competing Products
20 competing products in Thrombocytopenia Associated With Liver Disease